PureTech Health plc
PRTC.L
London Stock Exchange119.60
GBp
-0.60
- -
PureTech Health plc
PRTC.L
(London Stock Exchange)
Recent
price
119.60
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- PureTech Health plc is a clinical-stage biopharmaceutical company focused on discovering and developing new classes of medicines to address devastating diseases. Founded in 2015 and headquartered in London, United Kingdom, the company operates through a capital-efficient hub-and-spoke R&D model that advances therapeutic candidates internally and through a portfolio of Founded Entities supported by external capital. PureTech's product pipeline includes approximately 29 therapeutics and therapeutic candidates across various disease areas, with core products including deupirfenidone (LYT-100), a Phase 3-ready drug candidate aimed at treating idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases, and LYT-200, an anti-galectin-9 monoclonal antibody targeting hematological malignancies such as acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors like metastatic head and neck cancer. Recent developments include the launch of Celea Therapeutics in 2025 to advance deupirfenidone for lung fibrosis indications, marking an important strategic expansion focused on respiratory diseases. The company also launched Seaport Therapeutics, securing $100 million in funding to advance neuropsychiatric drug candidates, including a novel prodrug for generalized anxiety disorder. PureTech continues to progress LYT-200 through its Founded Entity Gallop Oncology, which has received FDA Fast Track and Orphan Drug designations for AML and demonstrated promising clinical activity in early trials. A notable milestone in 2024 was the FDA approval of Cobenfy (formerly KarXT), an antipsychotic treatment for schizophrenia developed by Karuna Therapeutics, a PureTech Founded Entity, which was acquired by Bristol Myers Squibb for approximately $14 billion. PureTech operates globally with a significant focus on the United States for clinical development and commercialization. Its strategy emphasizes identifying and de-risking high-potential assets, advancing them through strategic partnerships, equity holdings, milestone payments, and royalties while maintaining a strong financial position, including over $300 million in cash and equivalents as of mid-2025. The company targets markets including rare diseases, oncology, neuropsychiatric disorders, and pulmonary fibrosis, leveraging its innovative biotech platform and diversified portfolio to generate value for patients and shareholders. PureTech Health plc’s approach combines cutting-edge science with capital discipline, positioning it as a leading player in biotechnology innovation dedicated to transforming healthcare through novel therapeutics.
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
Cavendish sees Poolbeg’s POLB 001 gaining strategic importance as CRS research expands
Greengage plans AQSE float with bold Bitcoin-backed lending strategy
Puretech gains after FDA meeting post-Phase II trial
Coinsilium notes Greengage’s plan to float on Aquis